Cyclerion Therapeutics, Inc. (NASDAQ:KRSA - Get Free Report) has been given an average rating of "Moderate Buy" by the eight ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $51.20.
Several brokerages have recently commented on KRSA. UBS Group initiated coverage on Cyclerion Therapeutics in a research note on Friday, September 11th. They issued a "buy" rating and a $55.00 price target on the stock. Guggenheim initiated coverage on Cyclerion Therapeutics in a research report on Monday, September 28th. They set a "buy" rating and a $70.00 price objective for the company. TD Cowen assumed coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a "buy" rating on the stock. Wedbush began coverage on shares of Cyclerion Therapeutics in a report on Monday, October 5th. They issued an "outperform" rating and a $44.00 price objective on the stock. Finally, Wells Fargo & Company began coverage on shares of Cyclerion Therapeutics in a research report on Friday, November 13th. They issued an "overweight" rating and a $44.00 target price on the stock.
Get Our Latest Stock Analysis on Cyclerion Therapeutics
Cyclerion Therapeutics Stock Up 4.2%
KRSA opened at $36.93 on Friday. Cyclerion Therapeutics has a one year low of $7.19 and a one year high of $59.36. The firm has a market capitalization of $1.68 billion, a PE ratio of -2.91 and a beta of 1.85. The firm has a 50 day simple moving average of $32.29.
Cyclerion Therapeutics (NASDAQ:KRSA - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($3.19) earnings per share for the quarter, topping the consensus estimate of ($50.40) by $47.21. As a group, equities analysts predict that Cyclerion Therapeutics will post -5.35 earnings per share for the current year.
Institutional Investors Weigh In On Cyclerion Therapeutics
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Cyclerion Therapeutics in the 2nd quarter valued at approximately $57,000. Braidwell LP acquired a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth approximately $532,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth approximately $1,013,000. 75.62% of the stock is currently owned by institutional investors and hedge funds.
Cyclerion Therapeutics Company Profile
(
Get Free Report)
Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion's development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer's disease and other neurological disorders.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cyclerion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclerion Therapeutics wasn't on the list.
While Cyclerion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.